Monitoring the Effect of Vaccination on Mumps Cases Complications in the Czech Republic - Surveillance Data 2013–2022

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F25%3A00563904" target="_blank" >RIV/60162694:G44__/25:00563904 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/24:43927597 RIV/75010330:_____/24:00014704

Výsledek na webu

<a href="https://sciendo.com/journal/SJPH" target="_blank" >https://sciendo.com/journal/SJPH</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2478/sjph-2024-0027" target="_blank" >10.2478/sjph-2024-0027</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Monitoring the Effect of Vaccination on Mumps Cases Complications in the Czech Republic - Surveillance Data 2013–2022

Popis výsledku v původním jazyce

Introduction Mumps data were analysed to assess the effect of vaccination on mumps complications and hospitalisation. Methods The mumps cases reported to the Czech nationwide surveillance system from 2013 to 2022 were analysed using logistic regression with an odds ratio (aOR) adjusted for age, sex, year of onset and administrative region to measure the association between vaccination and complications or hospitalisation. Adjusted vaccine effectiveness (aVE) was calculated: aVE=(1-aOR)x100. Results A total of 11,913 mumps cases were reported, of which 6,885 (58%) were male. The median age of the study participants was 16 (range: 0–89 years). No complications occurred in 91% of patients. Mumps orchitis occurred in 633 (9%) male cases. A total of 946 (8%) patients required hospitalisation. The highest proportion of complications and hospitalisations was in the age group 35–44 years. Two doses of vaccine reduced statistically significantly the risk of any complications and of hospitalisation compared with unvaccinated patients: aOR 0.48 (95% CI: 0.37, 0.62), aVE of 52% (95% CI: 38, 63); and aOR 0.43 (95% CI: 0.33, 0.56), aVE of 57% (95% CI: 44, 67), respectively. Two doses showed statistically significant aVE 50% (95% CI: 32, 64) against orchitis, and 59% (95% CI: 23, 79) against meningitis. Among the two-dose recipients, the proportion of complications increased gradually with the time from the second dose. Conclusions Our findings demonstrated a protective effect of two-dose vaccination against mumps complications and hospitalisation for mumps. We recommend continuing routine childhood mumps vaccination and maintaining high MMR coverage in Czechia.

Název v anglickém jazyce

Monitoring the Effect of Vaccination on Mumps Cases Complications in the Czech Republic - Surveillance Data 2013–2022

Popis výsledku anglicky

Introduction Mumps data were analysed to assess the effect of vaccination on mumps complications and hospitalisation. Methods The mumps cases reported to the Czech nationwide surveillance system from 2013 to 2022 were analysed using logistic regression with an odds ratio (aOR) adjusted for age, sex, year of onset and administrative region to measure the association between vaccination and complications or hospitalisation. Adjusted vaccine effectiveness (aVE) was calculated: aVE=(1-aOR)x100. Results A total of 11,913 mumps cases were reported, of which 6,885 (58%) were male. The median age of the study participants was 16 (range: 0–89 years). No complications occurred in 91% of patients. Mumps orchitis occurred in 633 (9%) male cases. A total of 946 (8%) patients required hospitalisation. The highest proportion of complications and hospitalisations was in the age group 35–44 years. Two doses of vaccine reduced statistically significantly the risk of any complications and of hospitalisation compared with unvaccinated patients: aOR 0.48 (95% CI: 0.37, 0.62), aVE of 52% (95% CI: 38, 63); and aOR 0.43 (95% CI: 0.33, 0.56), aVE of 57% (95% CI: 44, 67), respectively. Two doses showed statistically significant aVE 50% (95% CI: 32, 64) against orchitis, and 59% (95% CI: 23, 79) against meningitis. Among the two-dose recipients, the proportion of complications increased gradually with the time from the second dose. Conclusions Our findings demonstrated a protective effect of two-dose vaccination against mumps complications and hospitalisation for mumps. We recommend continuing routine childhood mumps vaccination and maintaining high MMR coverage in Czechia.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30304 - Public and environmental health

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Zdravstveno Varstvo

ISSN

0351-0026

e-ISSN

1854-2476

Svazek periodika

63

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

SI - Slovinská republika

Počet stran výsledku

9

Strana od-do

205-213

Kód UT WoS článku

001318535600003

EID výsledku v databázi Scopus

2-s2.0-85205468649